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Abstract
Introduction: The variations in the Calpain-10 gene have been suggested to be related to susceptibility to type 2 diabetes mellitus (T2DM) 
in different populations. In this study, we investigated the relationship between single nucleotide polymorphism (SNP)-19, -44 and -63 
in the Calpain-10 gene and the development of T2DM in a Turkish population. 
Material and methods: A total of 211 subjects were recruited: 118 patients with a diagnosis of T2DM and 93 unrelated healthy subjects. 
Results: There were no significant differences in the genotype and allele distribution of SNPs studied between the patients with T2DM 
and controls (p > 0.05), whereas the frequencies of 121 haplotype and 122/121 haplotype combination were found to be higher in pa-
tients with T2DM than in controls (p < 0.05). No association was observed between the variations in the Calpain-10 gene and glycaemic 
control and lipid parameters (p > 0.05). The SNP-19 insertion/insertion was significantly related to increased body mass index (BMI) in 
male diabetic patients (p < 0.05). 
Conclusions: The present study indicates that 121 haplotype and 122/121 haplotype combination of SNP-19, -44 and -63 in the Calpain-10 
gene are associated with the development of T2DM in Turkish patients. (Endokrynol Pol 2014; 65 (2): 90–95)
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Streszczenie
Wstęp: Zmienność w genie kodującym kalpainę-10 wydaje się być związana z podatnością na cukrzycę typu 2 (T2DM) w różnych popu-
lacjach. Autorzy przeprowadzili badanie, w którym ocenili związek między polimorfizmem pojedynczego nukleotydu (SNP)-19, -44 i -63 
genu kodującego kalpainę-10 a rozwojem T2DM w tureckiej populacji. 
Materiał i metody: Do badania zrekrutowano 211 osób: 118 pacjentów z rozpoznaniem T2DM i 93 niespokrewnionych zdrowych osobników. 
Wyniki: Nie stwierdzono żadnych istotnych różnic w genotypie ani dystrybucji alleli badanych SNP między pacjentami z T2DM a osob-
nikami kontrolnymi (p > 0,05), choć częstości występowania haplotypu 121 i kombinacji haplotypów 122/121 była większa u pacjentów z 
T2DM niż osobników kontrolnych (p < 0,05). Nie stwierdzono powiązania między zmiennością genu kodującego kalpainę-10 a stopniem 
wyrównania glikemii i wartościami parametrów gospodarki lipidowej (p > 0,05). SNP-19 typu insercja/insercja wykazywał znamienny 
związek ze zwiększonym wskaźnikiem masy ciała (BMI) u mężczyzn z T2DM (p < 0,05). 
Wnioski: W przeprowadzonym badaniu wykazano, że haplotyp 121 oraz kombinacja haplotypów 122/121 SNP-19, -44 i -63 w genie 
kodującym kalpainę-10 wiążą się z rozwojem T2DM w populacji tureckiej. (Endokrynol Pol 2014; 65 (2): 90–95)
Słowa kluczowe: kalpaina-10;haplotyp; SNP;cukrzyca typu 2
Introduction 
Type 2 diabetes mellitus (T2DM) is an important meta-
bolic disease. The number of subjects with diabetes 
worldwide is expected to be 438 million in 2030 [1]. The 
pathogenesis of T2DM includes both genetic and envi-
romental factors, and identifying candidate genes encod-
ing proteins related to β-cell function, secretion and effect 
of insulin has increased in importance in recent years [2].
Calpain-10 is a member of the calpain superfamily 
[3]. The Calpain-10 protein which is synthesised from 
the Calpain-10 gene is an intracellular calcium-depend-
ent cysteine protease and essential for the function of 
various cell types [3]. The Calpain-10 gene may play a 
role in the regulation of insulin secretion and effect [4]. 
Horikawa et al. [5] first reported a significant associa-
tion between T2DM and the Calpain-10 gene, located 
on chromosome 2q37.3. Subsequent population studies 
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found that polymorphisms in the Calpain-10 gene were 
related to the development of T2DM [6–11]. But some 
studies have not supported this relationship [12–15]. 
Thus, it is important to investigate the relationship 
between the variations in the Calpain-10 gene and 
T2DM in different populations. The aim of the present 
study was to investigate the linkage between SNP-19, 
-44 and -63 in the Calpain-10 gene and the development 
of T2DM in Turkish subjects. Moreover, the possible 
associations of these polymorphisms with body mass 
index (BMI), glycaemic control and lipid parameters 
were examined. 
Material and methods
The present study was performed in 118 patients diagnosed 
with T2DM and 93 unrelated healthy control subjects with-
out diabetes. The patients and controls were recruited from 
subjects attending the outpatient diabetes, endocrine and 
internal medicine clinics of Gazi University. The diagnosis 
of T2DM was based on the American Diabetes Association 
(ADA) criteria [16]. To rule out diabetes or impared glucose 
tolerance, an oral glucose tolerance test was performed in 
control subjects. Detailed medical histories and the medica-
tions of the patients included in the study were recorded 
and physical examinations were performed. Height and 
weight were measured and BMIs were calculated. Fasting 
blood glucose (FBG), postprandial glucose (PPG), glycated 
haemoglobin (HbA1c), total cholesterol, low density lipo-
protein (LDL) cholesterol, high density lipoprotein (HDL) 
cholesterol, and triglycerides levels were measured from the 
collected blood samples. The study was approved by the 
Ethics Committee of Gazi University and informed consent 
was obtained from all subjects.
The Calpain-10 Single Nucleotide Polymorphism 
(SNP)-19, -44 and -63 genotyping were analysed using 
the polymerase chain reaction and restriction fragment 
length polymorphism (PCR-RFLP) method (Biometra, 
Germany) in extracted DNA from 10 ml peripheral 
blood samples. SNP-19 and -44 genotyping were stud-
ied in the samples from 118 patients and 93 controls, 
and SNP-63 genotyping was studied in the samples 
from 111 patients and 93 controls.
SNP-19
Forward primer 5’-GTTTGGTTCTCTTCAGCGT-
GCAG-3’ and reverse primer 5’-CATGAACCCTG-
GCAGGGTCTAAG-3’ were used for SNP-19 genotyping. 
PCR products were separated on 3% agarose gel and 
stained with ethidium bromide. The Calpain-10 SNP-19 
was an insertion/deletion polymorphism and consisted 
of two or three repeats of a 32 bp sequence. The allele 2 
(three repeats) was detected as a 178 bp band and allele 
1 (two repeats) was detected as a 146 bp band. 
SNP-44
Forward primer 5’-GCAGGGCGCTCACGCTTGCCG-3’ 
and reverse primer 5’-GCA TGGCCCCCTCTCT-
GATTC-3’ were used for SNP-44 genotyping. PCR 
products were digested with BstFNI restriction enzyme. 
The digested products were separated on 3% agarose 
gel and stained with ethidium bromide. Allele (C) was 
detected as a 166 bp band.
SNP-63
Forward primer 5’-AAGGGGGGCCAGGGCCT-
GACGGGGGTGGcG-3’ and reverse primer 5’-AG-
CACTCCCAGCTCTCGATC-3’ were used for SNP-63 
genotyping. PCR products were digested with HhaI re-
striction enzyme. The digested products were separated 
on 3% agarose gel and stained with ethidium bromide. 
Allele (C) was detected as a 192 bp band. 
Statistical analysis
Statistical analysis was performed using SPSS for 
Windows (Statistical Package for Social Science, ver-
sion 11.5; Chicago, IL, USA). All data was tested for 
normal distribution using the Kolmogorov-Smirnov 
test. Deviations from Hardy-Weinberg equilibrium was 
tested using χ2 goodness-of-fit test. Continuous vari-
ables were shown as arithmetic mean ± SD or median 
(minimum-maximum) and categorical variables were 
shown as number of subjects and ratio (%). Categori-
cal variables were compared by using Pearson χ2 test. 
Odds ratios (ORs) and their 95% confidence intervals 
(CIs) were calculated. Comparisons of the groups were 
examined by Student’s t test for normally distributed 
data and Mann Whitney U test for non-normally 
distributed data. One-Way ANOVA test was used to 
compare normally distributed data of three groups. 
p < 0.05 was considered statistically significant for all 
analyses. 
Results
The clinical and laboratory features of the patients 
and controls are set out in Table I. The allelic fre-
quencies of the SNP-19, -44 and -63 were in the 
Hardy-Weinberg equilibrium (p > 0.05). Since only 
one diabetic patient had SNP-44 CC genotype, TC/
CC ratio was used to compare the frequencies of 
the patients and controls instead of CC alone. The 
genotype and allele frequencies of the SNPs studied 
did not differ between the patients with T2DM and 
controls (p > 0.05) (Table II). Regarding the frequen-
cies of haplotype and haplotype combinations of 
SNP-19, -44 and -63; 121 haplotype was significantly 
more frequent in patients with T2DM compared to 
the control subjects (p < 0.05) and this haplotype was 
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found to be associated with a two times increased 
risk of T2DM [odds ratio (95% CI): 2.04 (1.04–4.01)] 
(Table III). Additionally, the frequency of 122/121 
haplotype combination was significantly higher in 
the patients with T2DM than in control subjects 
(p < 0.05) and this haplotype combination was associ-
ated with a four times increased risk of T2DM [odds 
ratio (95% CI): 4.01 (1.30–12.34)] (Table IV). 
BMI, FPG, PPG, HbA1c, and lipid parameters were 
not different with respect to the variations in the Cal-
pain-10 gene (p > 0.05). On the other hand, the male 
diabetic patients who had SNP-19 insertion/insertion 
showed significantly increased BMI compared to dele-
tion/deletion and deletion/insertion (31.5 ± 5.6, 28.1 ± 4.4 
and 27.3 ± 4.5, respectively; p < 0.05).
Discussion
In the present study, genotype and allele frequencies 
of SNP-19, -44 and -63 in the Calpain-10 gene did not 
differ between the patients with T2DM and controls. 
However, regarding haplotype and haplotype combina-
tions, we observed, as a new finding, that 121 haplotype 
and 122/121 haplotype combination of SNP-19, -44 and 
-63 are associated with two and four times increased 
risks of T2DM respectively. 
Table I. Clinical and laboratory features of the patients and controls
Tabela I. Cechy kliniczne i laboratoryjne pacjentów i osobników kontrolnych
Controls (n = 93) T2DM (n = 118)  p
Age (years) 38.6 ± 13.6 55.5 ± 10.0 < 0.001
Gender (F/M) 67/26 67/51 0.02
BMI [kg/m2] 26.3 ± 5.0 29.4 ± 5.1 < 0.001
Diabetes duration (years) – 5 (0.2–30.0) –
HbA1c (%) 5.3 (3.7–6.0) 6.6 (5.7–11.3) < 0.001
FPG [mg/dL] 87.0 (67.0–113.0) 133.0 (87.0–391.0) < 0.001
PPG [mg/dL] 99.0 (58.0–137.0) 172.0 (83.0–469.0) < 0.001
Total cholesterol [mg/dL] 182.5 (87.0–257.0) 182.0 (99.0–330.0) 0.65
HDL cholesterol [mg/dL] 42.0 (23.0–82.0) 41.0 (19.0–82.0) 0.19
LDL cholesterol[mg/dL] 112.8 (32.8–170.6) 100.6 (40.6–198.0) 0.53
Triglycerides [mg/dL] 123.0 (33–341.0) 154.0 (51.0–522.0) < 0.001
Data is expressed as mean ± standard deviation or median (minimum-maximum); T2DM — type 2 diabetes mellitus; BMI — body mass index; FPG — fasting plasma 
glucose; PPG — prandial plasma glucose
Table II. Genotype and allele frequencies of the Calpain-10 polymorphisms 
Tabela II. Częstości genotypowe i alleliczne polimorfizmów genu kodującego kalpainę-10 
Controls T2DM Controls T2DM
Genotype frequencies Allele frequencies
SNP-19 SNP-19
del/del 23 (24.7%) 22 (18.6%) deletion 97 (52.2%) 105 (44.5%)
del/ins 51 (54.8%) 61 (51.7%) insertion 89 (47.8%) 131 (55.5%)
ins/ins 19 (20.4%) 35 (29.7%)
SNP-44 SNP-44
TC/CC 37 (39.8%) 33 (28.0%) C 38 (20.4%) 33 (14.0%)
TT 56 (60.2%) 85 (72.0%) T 148 (79.6%) 203 (86.0%)
SNP-63 SNP-63
TT 35 (40.2%) 34 (30.6%) T 107 (61.5%) 126 (56.8%)
CT 37 (42.5%) 58 (52.3%) C 67 (38.5%) 96 (43.2%)
CC 15 (17.2%) 19 (17.1%)
T2DM — type 2 diabetes mellitus; del — deletion; ins — insertion; p values > 0.05
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The relationship between the Calpain-10 gene and 
the development of T2DM has been investigated in 
previous studies. But findings have varied according 
to different populations and ethnic groups. The study 
of Horikawa et al. [5] was the first to report that the 
Calpain-10 gene on chromosone 2 may contribute to the 
development of T2DM. In that study, SNP-19, -43 and 
-63 were found to be associated with T2DM in Mexican 
American and Northern European populations and 
112/121 haplotype combination was associated with 
a 2.8 times increased risk of T2DM in Mexican-Amer-
ican, 4.9 times in German and 2.5 times in Finnish 
populations [5]. They also suggested that polymor-
phisms in the Calpain-10 gene, not individually but in 
combination, account for the increased risk of T2DM. 
Chen et al. [17] reported that subjects who had 221 
haplotype of SNP-43, -56 and -63 showed increased 
risk of T2DM, whereas allele and genotype frequen-
Table III. Haplotype frequencies of the Calpain-10 polymorphisms
Tabela III. Częstości haplotypowe polimorfizmów genu kodującego kalpainę-10
Haplotype Controls (n = 87) T2DM (n =111) Odds ratio (95% CI)
111 25 (28.7%) 36 (32.4%) 1.19 (0.64–2.19)
121 16 (18.3%) 35 (31.5%) 2.04 (1.04–4.01)*
221 1 (1.1%) 4 (3.6%) 3.21 (0.35–29.25)
212 12 (13.7%) 9 (8.1%) 0.55 (0.22–1.37)
112 30 (34.4%) 31 (27.9%) 0.66 (0.36–1.21)
122 53 (60.9%) 75 (67.5%) 1.28 (0.71–2.30)
211 19 (21.8%) 18 (16.2%) 0.69 (0.33–1.41)
T2DM — type 2 diabetes mellitus; CI — confidence interval ‘ * p < 0.05; SNP-44: allele 1 T, allele 2 C, SNP-19: allele 1 del, allele 2 ins, SNP-63: allele 1 C, allele 2 T; 
Code 1: alleles of SNP-44, code 2: alleles of SNP-19 and code 3: alleles of SNP-63 in haplotypes 
Table IV. Haplotype combination frequencies of the Calpain-10 polymorphisms
Tabela IV. Częstości kombinacji haplotypów polimorfizmów genu kodującego kalpainę-10
Haplotype Controls (n=87) T2DM (n=111) Odds ratio (95% CI)
212/112 3 (3.4%) 1 (0.9%) 0.25 (0.02–2.49)
212/122 9 (10.3%) 8 (7.2%) 0.67 (0.24–1.82)
211/211 1 (1.1%) – –
211/112 5 (5.7%) 8 (7.2%) 1.27 (0.40–4.04)
211/111 1 (1.1%) 1 (0.9%) 0.78 (0.04–12.68)
211/122 10 (11.5%) 6 (5.4%) 0.44 (0.15–1.26)
211/121 2 (2.3%) 3 (2.7%) 1.18 (0.19–7.22)
112/112 3 (3.4%) 1 (0.9%) 0.25 (0.02–2.49)
112/122 11 (12.6%) 14 (12.6%) 0.99 (0.42–2.32)
111/111 1 (1.1%) 1 (0.9%) 0.78 (0.04–12.68)
111/112 8 (9.2%) 7 (6.3%) 0.66 (0.23–1.91)
111/122 9 (10.3%) 16 (14.4%) 1.46 (0.61–3.48)
111/121 6 (6.9%) 11 (9.9%) 1.48 (0.52–4.18)
222/122 3 (3.4%) – –
221/122 1 (1.1%) 3 (2.7%) 2.38 (0.24–23.37)
221/121 – 1 (0.9%) –
122/122 6 (6.9%) 10 (9.0%) 1.33 (0.46–3.83)
122/121 4 (4.6%) 18 (16.2%)  4.01 (1.30–12.34)*
121/121 4 (4.6%) 2 (1.8%) 0.38 (0.06–2.12)
T2DM — type 2 diabetes mellitus; CI — confidence interval; * p < 0.05; SNP-44: allele 1 T, allele 2 C, SNP-19: allele 1 del, allele 2 ins, SNP-63: allele 1 C, allele 2 T; 
Code 1: alleles of SNP-44, code 2: alleles of SNP-19 and code 3: alleles of SNP-63 in haplotypes 
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cies of these SNPs did not differ between T2DM and 
controls in Nigerians. In a study evaluating SNP-43, 
-19 and -63 haplotype combinations, SNP-43 A allele 
was found to be associated with the risk of T2DM, and 
121/221 haplotype combination was associated with 
T2DM, in a Tunisian population [18]. The study of Adak 
et al. [19] showed that the SNP-63 T allele and 112 hap-
lotype combination of SNP-43, -19 and -63 were related 
to an increased risk of T2DM in an Indian population. 
In another study from the same population, those SNPs 
showed no significant differences between T2DM and 
controls individually but, when combined, 2111 haplo-
type combination was found to be associated with the 
development of T2DM [9]. Moreover, Orho-Malender 
et al. [20] reported SNP-43 G allele, SNP-63 T allele and 
1121/1121 haplotype combination of SNP-44, 43, -19 
and -63 to be related to the risk of T2DM in a Finnish 
population. Similarly, Cassell et al. [7] found that sub-
jects with a 1112/1121 haplotype combination of the 
same polymorphisms had a 5-6 times increased risk 
of T2DM in an Indian population. Regarding SNP-44 
alone, it has been reported that SNP-44, located in intron 
3 and 11 bp from SNP-43, was independently associ-
ated with T2DM in an English population [21]. Also, 
a meta-analysis on the association between SNP-44 and 
T2DM showed that SNP-44 significantly contributes to 
the susceptibility to T2DM [22]. Also, a previous study 
from our country reported that SNP-44 TC genotype 
in the Calpain-10 gene was associated with T2DM in 
Turkish subjects [23]. The importance of our study is the 
haplotype analyses performed. These analyses showed 
that SNPs in the Calpain-10 gene in the development of 
T2DM are more prominent when combined. 
Additionally, there have been other reports show-
ing the possible protective effect of Calpain-10 gene 
on T2DM. Wu et al. [24] reported that the presence of 
112/221 haplotype combination of SNP-43, -19 and -63 
may have a protective role in the development of T2DM. 
A study from a Northern Han Chinese population [25] 
also suggested that 1112/1221 haplotype combination of 
SNP-44, -43, -19 and -63 is a protective factor for T2DM. 
In our study, we did not observe any protective effects 
of SNPs studied on the development of T2DM.
On the other hand, some previous studies have 
reported a lack of association between SNPs in the 
Calpain-10 gene and T2DM. The study of Evans et al. 
[21] found that SNP-19, -43 and -63 in the Calpain-10 
gene did not contribute to the risk for T2DM in an 
English population. In line with this data, Malecki et 
al. [6] observed similar genotype, allele and haplotype 
frequencies of SNP-19 -43 and -63 in either T2DM or con-
trols in a Polish population. However, they suggested 
that 121/121 haplotype combination may increase the 
development of T2DM only in patients with a positive 
family history of diabetes. Additionally, the study of 
Rasmussen et al. [26] in Scandinavians and the study 
of Fingerlin et al. [14] in a Finnish population did not 
find any relationship between the SNP-19, -43, -56, -63 
in the Calpain-10 gene and the development of T2DM. 
These controversial results may arise from ethnic het-
erogeneity or possible interactions between genetic, 
behavioural and enviromental factors. 
Regarding the mechanisms by which Calpain-10 
gene influences the development of T2DM, Baier et al. 
[27] suggested that polymorphisms in the Calpain-10 
gene lead to decreases in glucose oxidation and turno-
ver in skeletal muscle in Pima Indians with normal glu-
cose tolerance. Another study showed that Calpain-10 
polymorphisms are associated with insulin resistance 
and increased free fatty acids [20]. A recent study also 
showed that a polymorphism in the Calpain-10 gene 
may have an effect on insulin sensitivity in metabolic 
syndrome [28]. However, the underlying mechanisms 
of the relationship between the Calpain-10 gene and 
T2DM are not fully known. 
A recent animal study suggested that Calpain-10 
may have a role in the regulation of obesity in mice 
[29]. In the present study, we observed that the SNP-
19 (insertion/insertion) is associated with increased 
BMI in male diabetic patients. In accord with our result, 
Shima et al. [30] found that SNP-19 insertion/insertion 
is associated with increased BMI in both genders. De-
mirci et al. [23] also reported increased BMI in patients 
with T2DM who had SNP-44 TC genotype. Similarly, 
the frequency of SNP-44 CC genotype was found to 
be increased in obese patients with T2DM compared 
to non-obese patients [25]. 
Taken together, Calpain-10 gene may be a risk factor 
for obesity in patients with T2DM. In our study, the rea-
son why the relationship between SNP-19 and increased 
BMI has been detected only in men is unclear. Most 
previous studies on Calpain-10 did not find a gender-
specific effect of this gene on metabolic parameters. On 
the other hand, a previous study including offspring of 
patients with T2DM showed that SNP-43, but not SNP-
19 or -44, was associated with the intra-abdominal fat 
area in men and the authors suggested that Calpain-10 
may increase the risk of T2DM via affecting abdominal 
obesity in men with high risk for T2DM [31]. Therefore, 
the relationship between Calpain-10 and increased BMI 
in men presented in our study needs to be investigated 
extensively. 
In conclusion; although we found similar genotype 
and allele frequencies between the patients with T2DM 
and controls, we showed that 121 haplotype and 122/121 
haplotype combination of SNP-19, -44 and -63 in the 
Calpain-10 gene were associated with the development 
of T2DM in this Turkish population. 
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